Journal Article Review Ppublish
PubMed: 40694958 DOI: 10.1016/j.redox.2025.103776
Reactive oxygen species in polycystic ovary syndrome: Mechanistic insights into pathogenesis and therapeutic opportunities.
Redox Biol 85:103776
Authors: Huanju Liu, Lihao Jin, Xiaoya Wang, Junling Shi, Yujie He, Ningxia Sun, Fu Yang
Affiliations
- Department of Medical Genetics, Naval Medical University, Shanghai, China.
- Institute of Genetics, International School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Center for Reproductive Medicine, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
- Center for Reproductive Medicine, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
- Department of Medical Genetics, Naval Medical University, Shanghai, China; Center for Reproductive Medicine, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Abstract
Polycystic ovary syndrome (PCOS), a common yet intricate endocrine disorder, presents persistent clinical challenges due to its complex pathogenesis. Reactive oxygen species (ROS), highly reactive molecules, have emerged as critical contributors to PCOS development and represent potential therapeutic targets. This review comprehensively explores the diverse roles of ROS in PCOS pathogenesis, particularly their contributions to metabolic dysfunction and hormonal imbalance. It further assesses the therapeutic potential of ROS-targeted interventions, summarizing antioxidant therapy advancements, underlying mechanisms, and current challenges. By consolidating recent research, this review highlights the profound significance of ROS in PCOS, aiming to inspire innovative pathogenesis research, improve clinical management, and establish a robust theoretical foundation for more effective PCOS treatment strategies.
MeSH
Ovary, Polycystic Ovary Syndrome, Research, Therapeutics